CDMO Scale-Up: Moving a Process From Development to Manufacturing

A successful laboratory batch can create a false sense of certainty.

The product was made.

The process worked.

So manufacturing should simply mean doing the same thing in a larger vessel.

In practice, scale-up is rarely that simple.

Increasing production can change how materials mix, heat moves through equipment, reactions behave, cells grow, filtration performs, or purification steps operate.

The underlying science may still be sound.

The manufacturing process may still need significant work.

Scale-up is the process of increasing production from a smaller development environment toward the scale required for clinical or commercial manufacturing.

The details vary widely by modality.

For a small molecule, scale-up might involve moving a chemical reaction into larger reactors.

For a biologic, it may involve increasing cell-culture volume and adjusting upstream and downstream operations.

For a drug product, it could involve moving formulation, filling, tablet production, or another operation to larger equipment.

The objective is not merely to produce more material.

The process still has to produce material with the appropriate quality and consistency.

Manufacturing equipment is not simply a larger version of laboratory glassware.

As scale changes, factors such as:

• mixing
• heat transfer
• mass transfer
• processing time
• equipment geometry
• filtration
• material handling

can change as well.

Those differences can affect process performance.

This is why a CDMO's scale-up experience with the relevant type of product matters.

A sponsor needs to know which parts of the process are sensitive before increasing scale.

The development team should understand, to the extent appropriate for the stage:

• important process parameters
• sources of variability
• product quality attributes
• known failure points
• equipment dependencies
• material dependencies

The better the process is understood, the easier it becomes to identify what might change at larger scale.

Early development equipment is often selected for speed and flexibility.

Manufacturing equipment is selected for controlled and repeatable production.

Those environments may use different:

• vessel sizes
• mixers
• pumps
• filters
• chromatography systems
• filling lines
• control systems

A process that depends heavily on a particular development setup may need adaptation before it can move into the manufacturing facility.

A sponsor may be changing both scale and location at the same time.

That means the CDMO is not only receiving the process.

It may also be adapting it to:

• new equipment
• new operators
• new facility procedures
• larger production scale

Those two changes can make the project more complicated than a straightforward technology transfer.

Sponsors should be clear about whether the proposed scope includes scale-up development.

Depending on the product and stage, the CDMO may recommend an engineering or non-GMP run before the first GMP batch.

This can help the team evaluate:

• equipment compatibility
• process timing
• scale-related behavior
• operator procedures
• sampling
• analytical performance

An engineering run is not automatically necessary for every program.

It is one tool that may reduce uncertainty before a higher-stakes manufacturing campaign.

For biologics, scale-up can affect upstream and downstream processing.

The team may need to consider:

• culture conditions
• bioreactor characteristics
• mixing
• oxygen transfer
• harvest
• filtration
• chromatography
• concentration

A biologics CDMO should have relevant experience moving processes across the scales the program expects to use.

Small molecule process scale-up may involve:

• reaction kinetics
• heat management
• mixing
• impurity formation
• crystallization
• filtration
• drying
• process safety

A synthetic route that is convenient in the laboratory may need modification before larger-scale production.

This is why process development and scale-up frequently overlap.

Drug product manufacturing can also change as scale increases.

For an oral solid dose product, the sponsor may need to scale:

• blending
• granulation
• drying
• compression
• coating

For a sterile product, scaling may involve:

• formulation
• batch preparation
• filtration
• filling
• lyophilization

The manufacturing partner should be selected based on the product and process being scaled.

Scaling the process is difficult if the analytical package cannot reliably measure performance and product quality.

Sponsors should make sure methods are appropriate for the stage and capable of supporting development decisions.

A manufacturing problem discovered during scale-up may actually expose an analytical weakness.

The two workstreams are closely connected.

A laboratory may use materials that are easy to purchase in small quantities.

Larger-scale manufacturing may require:

• greater quantities
• different packaging
• qualified suppliers
• longer lead times
• alternate sources

Sponsors should review critical raw materials as part of the scale-up plan.

The process is not scalable if essential inputs cannot be supplied reliably.

Early-stage companies sometimes try to solve commercial manufacturing before they have generated clinical data.

That can lead to unnecessary complexity.

The opposite problem also exists.

A sponsor may choose a small-scale partner without considering that a successful program could require a difficult transfer later.

The right balance depends on:

• development stage
• expected demand
• technical risk
• financing
• transfer complexity

There is no universal rule that one CDMO should support every stage.

Useful conversations should go beyond:

“Can you manufacture at this scale?”

Ask:

• What scale-up work do you expect?
• Which process steps concern you most?
• What equipment differences exist?
• Would you recommend an engineering run?
• What development data do you need?
• How will the analytical methods support scale-up?
• What could change the schedule?
• What would make the process unsuitable for this facility?

A manufacturer willing to discuss risk openly can be more useful than one that simply promises the process will transfer smoothly.

A facility may have equipment large enough to support the required batch.

That does not mean the equipment is available when the sponsor needs it.

Scale answers:

Can this facility produce the required amount?

Capacity answers:

Can it do so within the required timeframe?

Sponsors need both.

Pharma Connect Navigator helps sponsors evaluate potential manufacturing partners based on the requirements and stage of a specific program.

Sponsors can define manufacturing scale, development stage, required capabilities, timing, regulatory needs, geography, budget, and support requirements.

PCN helps identify potentially relevant CDMO companies and facilities and provides a structured way to compare project fit.

Facility and equipment information, where available, can help sponsors narrow the market before detailed scale-up and technology-transfer discussions begin.

PCN does not perform process scale-up or determine technical feasibility. Those decisions require direct work between the sponsor, CDMO, and qualified technical teams.